Management Team

Dr. Wang joined IASO Biotherapeutics in March 2020, and is currently the company’s Chief Executive Officer.

Dr. Wang graduated from Anhui Medical University with a Bachelor of Medicine (B.M.) degree. He was an orthopedic resident doctor and attending physician in Shanghai TCM Integrated Hospital. Dr. Wang subsequently obtained Master of Medicine (M.M.) degree from Tongji University and Doctor of Medicine (M.D.) degree from Tongji University/ Universität Würzburg, as well as doctorate in molecular biology (Ph.D.) from University of Aberdeen. He was a post-doctoral fellow in the University of Connecticut Health Center, during which he published over 20 papers in SCI-indexed journals on cell therapies in leading publications including Clinical Cancer Research and Blood.

Dr. Wang joined the pharma industry in 2013, having worked with Cellular Biomedicine Group (NASDAQ: CBMG), JW Therapeutics (SEHK: 02126), and Simecere Pharmaceutical Group (SEHK: 02096) as Medical Director, Head of Clinical Development and Head of Clinical Sciences, respectively.

Dr. Wang has been exploring cell therapies since 2006. As a key member of the project team, he contributed to the successful investigational new drug application for the first CD19-targeted CAR-T therapy in China.

He was appointed Chief Medical Officer of IASO Biotherapeutics in March 2020, leading the clinical development team in the clinical trial of CT103A. In April 2021, Dr. Wang was appointed Chief Executive Officer, responsible for day-to-day operation and management.

Dr. He brings to IASO Biotherapeutics more than 30 years of experience with an excellent track record of successfully developing novel oncology therapies and conducting biomedical research. He has extensive experience in the process development and GMP production of cellular immunotherapies and biological products.

Previously, Dr. He held leadership positions in innovative biotech and global pharmaceutical companies such as Clover Bio, Legend Bio, and Boehringer Ingelheim in China and the United States. As a key decision-maker, he led technical operations teams in successfully achieving GMP compliant manufacturing and BLA filings in accordance with FDA/ NMPA/ EMA/ICH guidelines.

David holds a Ph.D. in Pathogenic Biology from Sun Yat-sen University, and completed postdoctoral research in immunology at the University of Alabama at Birmingham.

Dr. Fu combines rich experiences in finance with a deep knowledge in science. While at Haitong International and Citigroup he led numerous successful listings of Chinese companies in Hong Kong and the United States, including multiple companies in the healthcare industry. Prior to that, Dr. Fu worked for two law firms-Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto-where he focused on capital markets transactions, including IPOs and bond issuances. Early in his career, he was a scientist at Rigel Pharmaceuticals, a US-based biotechnology company, focusing on research and drug development in the immunology and oncology areas.

Dr. Fu holds a J.D. degree from University of California, Berkeley School of Law, a Ph.D. degree in Molecular Genetics from Washington University School of Medicine in St. Louis, an M.S. degree in Molecular Immunology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences and a B.S. degree in Genetics and Genetic Engineering from Fudan University.

Mr. Zou joined IASO Biotherapeutics in 2017 and is currently the company’s Director and Vice President for CMC. He has nearly 20 years of experience in GMP management.

Mr. Zou graduated from the National University of Singapore with a Master’s degree in Chemistry, and was previously Quality Director and Quality Authorizer of Sinovac Biotech Ltd. (NASDAQ: SVA). He was also a GMP Expert of Beijing Municipal Medical Products Administration.